HW
LXRX icon

Hancock Whitney’s Lexicon Pharmaceuticals LXRX Stock Holding History

Hancock Whitney’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-245,434
Closed -$479K – 837
2020
Q1 		$479K Buy
+245,434
New +$731K 0.02% 518
2016
Q3 		– Sell
-664,025
Closed -$9.53M – 578
2016
Q2 		$9.53M Buy
664,025
+2,280
+0.3% +$30.9K 0.4% 116
2016
Q1 		$7.91M Buy
661,745
+14,350
+2% +$150K 0.33% 136
2015
Q4 		$8.62M Buy
+647,395
New +$7.96M 0.36% 120

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
UL
Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Hancock Whitney's LXRX Position: Q2 2020 in Review

Hancock Whitney sold out of Lexicon Pharmaceuticals (LXRX) in Q2 2020, closing a stake of 245,434 shares — an estimated $479K sold.

Hancock Whitney first reported a position in LXRX in Q4 2015 and held it in 4 quarters. The position peaked at $9.53M in Q2 2016. 108 funds tracked by Wall St. Rank hold LXRX as of Q2 2020.

  • Hancock Whitney reported no remaining Lexicon Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • Hancock Whitney sold 245,434 Lexicon Pharmaceuticals shares in Q2 2020, an estimated $479K.
  • Hancock Whitney first reported a position in Lexicon Pharmaceuticals in Q4 2015 and held it in 4 quarters.
  • Hancock Whitney's Lexicon Pharmaceuticals position peaked at $9.53M in Q2 2016.
  • 108 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2020.

Based on Hancock Whitney's 13F filing for Q2 2020, filed 30 Jul 2020.